Get the Stockscreener App
4.13
2.48%
0.10
After Hours:
4.10
-0.03
-0.73%
Voyager Therapeutics Inc stock is traded at $4.13, with a volume of 405.96K.
It is up +2.48% in the last 24 hours and down -2.36% over the past month.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
See More
Previous Close:
$4.03
Open:
$3.94
24h Volume:
405.96K
Relative Volume:
0.59
Market Cap:
$246.15M
Revenue:
$40.37M
Net Income/Loss:
$-119.72M
P/E Ratio:
-2.0243
EPS:
-2.0402
Net Cash Flow:
$-135.06M
1W Performance:
+10.43%
1M Performance:
-2.36%
6M Performance:
-8.63%
1Y Performance:
+13.46%
1-Day Range:
$3.94
$4.22
1-Week Range:
$3.685
$4.22
52-Week Range:
$2.645
$5.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Name
Voyager Therapeutics Inc
Sector
Industry
Phone
857-259-5340
Address
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
4.13 | 240.19M | 40.37M | -119.72M | -135.06M | -2.0402 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-02-24 | Initiated | Citigroup | Buy |
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Oct-16-24 | Initiated | Leerink Partners | Outperform |
| Mar-26-24 | Initiated | Guggenheim | Buy |
| Mar-19-24 | Initiated | H.C. Wainwright | Buy |
| Mar-07-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-10-23 | Initiated | Truist | Buy |
| Mar-10-23 | Initiated | Oppenheimer | Outperform |
| Oct-07-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-03-21 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-03-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-24-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-23-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-10-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-19-20 | Initiated | The Benchmark Company | Buy |
| Feb-06-20 | Initiated | Oppenheimer | Outperform |
| Nov-15-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Sep-10-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-18 | Initiated | H.C. Wainwright | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-12-18 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-02-18 | Initiated | Morgan Stanley | Overweight |
| Nov-28-17 | Resumed | Piper Jaffray | Overweight |
| Oct-31-17 | Initiated | Robert W. Baird | Outperform |
| Oct-27-17 | Initiated | Canaccord Genuity | Buy |
| Oct-23-17 | Reiterated | Stifel | Buy |
| Oct-12-17 | Initiated | Raymond James | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-28-17 | Resumed | Stifel | Buy |
View All
Voyager Therapeutics Inc Stock (VYGR) Latest News
Short Covering: Can Voyager Therapeutics Inc reach all time highs this year2026 Sector Review & Breakout Confirmation Alerts - baoquankhu1.vn
Citi Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Is Voyager Therapeutics Inc stock a smart retirement pickMarket Trend Review & Breakout Confirmation Alerts - baoquankhu1.vn
Voyager Therapeutics Conference: CEO Calls 2026 “Year of Tau,” Eyes BBB Capsid Clinic Debut - Yahoo Finance
If You Invested $1,000 in Voyager Therapeutics Inc (VYGR) - Stock Titan
Published on: 2026-03-22 03:58:04 - baoquankhu1.vn
HC Wainwright Analysts Increase Earnings Estimates for VYGR - MarketBeat
VYGR Forecast, Price Target & Analyst Ratings | VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) - ChartMill
Voyager Therapeutics at Stifel 2026 CNS Forum: Year of Tau Focus - Investing.com Canada
H.C. Wainwright reiterates Voyager Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Analysts Set Expectations for VYGR Q1 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Voyager Therapeutics (VYGR) and Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Voyager Therapeutics (VYGR): Analyst Reiterates Buy Rating and M - GuruFocus
Voyager Therapeutics' (VYGR) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Truist reiterates Buy on Voyager Therapeutics stock ahead of data By Investing.com - Investing.com Canada
Truist reiterates Buy on Voyager Therapeutics stock ahead of data - Investing.com
Voyager Therapeutics Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
Voyager Therapeutics Stock (ISIN: US92916U1025) Eyes Major Upside Amid Gene Therapy Pipeline Momentu - AD HOC NEWS
Voyager Therapeutics (NASDAQ:VYGR) Upgraded to Hold at Wall Street Zen - MarketBeat
Insider Trends: Can Voyager Therapeutics Inc reach all time highs this year - baoquankhu1.vn
Is Voyager Therapeutics (VYGR) Balancing Pipeline Ambition With Sustainable Losses After Its 2025 Results? - Sahm
Does Voyager Therapeutics’ (VYGR) Widening Annual Loss Redefine the Risk-Reward in Its Neurology Pipeline? - Yahoo Finance
Guggenheim Remains a Buy on Voyager Therapeutics (VYGR) - The Globe and Mail
Wells Fargo Sticks to Their Buy Rating for Voyager Therapeutics (VYGR) - The Globe and Mail
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Voyager Therapeutics Faces Rising Tariff and U.S.–China Geopolitical Risks as BIOSECURE Act Threatens Key Chinese CDMO Partnerships - The Globe and Mail
Voyager Therapeutics (VYGR) Gets a Buy from H.C. Wainwright - The Globe and Mail
Voyager Therapeutics (VYGR) Q4 Loss Of US$27 Million Reinforces Bearish Profitability Concerns - simplywall.st
Voyager Therapeutics, Inc. 2025 Annual Report: Key Risks, Forward-Looking Statements, and Business Overview - Minichart
Voyager Therapeutics Inc earnings beat by $0.05, revenue topped estimates - Investing.com Australia
Voyager Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Voyager Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Voyager Therapeutics Q4 2025 Financial Report: Revenue Surpasses EstimatesNews and Statistics - IndexBox
Voyager (VYGR) Surpasses Q4 Revenue Expectations, Sets Strategic Vision for 2026 - GuruFocus
Voyager Therapeutics: Fourth Quarter Earnings Overview - Bitget
Gene therapy pioneer Voyager Therapeutics Inc (stock code: VYGR) announced that by the end of fiscal year 2025, the company held strong cash and cash equivalents totaling $202 million. - Bitget
Voyager Therapeutics (NASDAQ:VYGR) Announces Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat
Voyager Therapeutics: Q4 Earnings Snapshot - 10tv.com
Voyager Therapeutics reports Q4 2025: $15.3M Q4 collaboration revenue, $119.7M full-year net loss - TradingView
Voyager Therapeutics Q4 net loss narrows - TradingView
Voyager Therapeutics 2025 10-K: Collaboration revenue $40.4M, Net loss $(119.7)M - TradingView
Voyager (Nasdaq: VYGR) 2025 loss but cash runway into 2028 - Stock Titan
Earnings Breakdown: Voyager Therapeutics Q4 - Benzinga
BRIEF-Voyager Therapeutics Q4 EPS USD -0.46 - TradingView
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - GlobeNewswire
Is Voyager Therapeutics Inc. stock trading at a premium valuation2026 Summary & Expert-Curated Trade Recommendations - Naître et grandir
Will Voyager Therapeutics Inc. stock gain from lower inflationEarnings Growth Report & Fast Entry Momentum Alerts - mfd.ru
VYGR Earnings History & Surprises | EPS & Revenue Results | VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) - ChartMill
Voyager Therapeutics Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Voyager Therapeutics (VYGR) to Release Quarterly Earnings on Tuesday - MarketBeat
Voyager Therapeutics Inc Stock (VYGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):